Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations
Microbiology Spectrum · 15.06.2023 · 11 (3)
DOI: 10.1128/spectrum.01339-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 15.06.2023. Verfasst von Shawn Flanagan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cidara Therapeutics, Inc., San Diego, California, USA. Hauptthemen laut MEDLINE: Candidiasis, Echinocandins. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cidara Therapeutics.
Abstract (Originalsprache)
Antifungal agents used to treat life-threatening infections are often associated with severe drug-drug interactions (DDIs) that may limit their usefulness. Rezafungin, a newly approved once-weekly echinocandin, has been shown to be free of DDIs based on extensive nonclinical and clinical testing described in this study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cidara Therapeutics, Inc., San Diego, California, USA.
- Mundipharma Ltd., Cambridge, United Kingdom.
ORCID-Profile: Voon Ong
Förderung
- Cidara Therapeutics
Zitieren
APA
Flanagan, S., Walker, H., Ong, V., & Sandison, T. (2023). Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations. Microbiology Spectrum, 11(3). https://doi.org/10.1128/spectrum.01339-23
Vancouver
Flanagan S, Walker H, Ong V, Sandison T. Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations. Microbiology Spectrum. 2023;11(3). doi:10.1128/spectrum.01339-23
BibTeX
@article{Flanagan2023,
author = {Flanagan, Shawn and Walker, Helen and Ong, Voon and Sandison, Taylor},
title = {Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations},
journal = {Microbiology Spectrum},
year = {2023},
volume = {11},
number = {3},
doi = {10.1128/spectrum.01339-23}
}
EUVIMED